Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

Biology of Blood and Marrow Transplantation(2020)10.1016/j.bbmt.2020.04.015Source: DataRank Database

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia is a research paper published in Biology of Blood and Marrow Transplantation (2020). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.69)OA: hybridTopics (42)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Ni‐Chun Tsai,Sally Mokhtari,Monzr M. Al Malki ORCID,Haris Ali ORCID,Amandeep Salhotra ORCID

Live enrichment

PubMed:32416253 PMC:PMC8822504 OpenAlex:https://openalex.org/W3025676134

National Institutes of Health

Grant: P30 CA033572

FWCI

0.69

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.bbmt.2020.04.015

publisherhttps://doi.org/10.1016/j.bbmt.2020.04.015

publisherhttps://api.elsevier.com/content/article/PII:S1083879120302275?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1083879120302275?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32416253

Fields of Study

Acute Lymphoblastic Leukemia researchHematopoietic Stem Cell TransplantationChildhood Cancer Survivors' Quality of LifeAgedGraft vs Host DiseaseHumansMelphalanPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesSirolimusTacrolimusTransplantation ConditioningVidarabine

MeSH Terms

AgedGraft vs Host DiseaseHumansMelphalanRetrospective StudiesVidarabineTacrolimusHematopoietic Stem Cell TransplantationTransplantation ConditioningSirolimusPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

MedicineCumulative incidenceMelphalanFludarabineSirolimusInternal medicineTacrolimusOncologyGraft-versus-host diseaseRegimenSurgeryIncidence (geometry)TransplantationChemotherapyCyclophosphamideAcute lymphoblastic leukemiaTacrolimus And Sirolimus Gvhd Prophylactic RegimenReduced-intensity Conditioning With Fludarabine And Melphalan

Sustainable Development Goals

SDG 0: Good health and well-being